Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
SMTI 
Sanara Medtech Inc (SMTI)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: SMTI (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $49.5
1 Year Target Price $49.5
| 1 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -48.36% | Avg. Invested days 20 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 270.19M USD | Price to earnings Ratio - | 1Y Target Price 49.5 |
Price to earnings Ratio - | 1Y Target Price 49.5 | ||
Volume (30-day avg) 2 | Beta 1.26 | 52 Weeks Range 23.53 - 39.08 | Updated Date 08/15/2025 |
52 Weeks Range 23.53 - 39.08 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.16 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-08-13 | When - | Estimate -0.485 | Actual -0.23 |
Profitability
Profit Margin -10.22% | Operating Margin (TTM) -0.12% |
Management Effectiveness
Return on Assets (TTM) -2.5% | Return on Equity (TTM) -26.38% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 307732341 | Price to Sales(TTM) 2.78 |
Enterprise Value 307732341 | Price to Sales(TTM) 2.78 | ||
Enterprise Value to Revenue 3.36 | Enterprise Value to EBITDA -29.03 | Shares Outstanding 8887850 | Shares Floating 3599572 |
Shares Outstanding 8887850 | Shares Floating 3599572 | ||
Percent Insiders 65.34 | Percent Institutions 12 |
Upturn AI SWOT
Sanara Medtech Inc
Company Overview
History and Background
Sanara Medtech Inc., formerly known as Wound Management Technologies, Inc., was founded in 2007. It has focused on developing and marketing wound and skin care products. The company evolved through acquisitions and strategic shifts, focusing on regenerative medicine and advanced wound care.
Core Business Areas
- Wound and Skin Care Products: Development, marketing, and distribution of wound and skin care products, including advanced wound dressings, biologics, and devices used in wound healing and surgical tissue repair.
Leadership and Structure
Ron Nixon serves as the CEO and Chairman. The company has a board of directors and a management team responsible for overseeing various functional areas, including sales, marketing, research and development, and operations.
Top Products and Market Share
Key Offerings
- CellerateRX Surgical Activated Wound Powder: A surgical powder indicated for partial and full-thickness wounds, pressure ulcers, venous stasis ulcers, diabetic ulcers, burns, surgical wounds, trauma wounds, and draining wounds. Market share data is not publicly available. Competitors include Integra LifeSciences and Acelity (now part of 3M).
Market Dynamics
Industry Overview
The advanced wound care market is characterized by technological innovation, growing aging population, and increasing prevalence of chronic diseases like diabetes. The market is competitive, with established players and emerging companies vying for market share.
Positioning
Sanara Medtech positions itself as a provider of innovative regenerative medicine and wound care solutions. Its competitive advantages likely include proprietary technologies and strong relationships with healthcare providers.
Total Addressable Market (TAM)
The global advanced wound care market is estimated to be in the billions of dollars. Sanara Medtech is positioned to capture a portion of this TAM through its specialized products and targeted marketing strategies.
Upturn SWOT Analysis
Strengths
- Proprietary technologies
- Focus on regenerative medicine
- Established sales and marketing infrastructure
- Experienced management team
Weaknesses
- Limited product portfolio compared to larger competitors
- Relatively small market capitalization
- Dependence on key products for revenue generation
Opportunities
- Expanding into new geographic markets
- Developing new products and applications
- Acquiring complementary technologies or businesses
- Capitalizing on the growing aging population and chronic disease prevalence
Threats
- Competition from larger, more established players
- Pricing pressures from managed care organizations
- Regulatory changes impacting product approvals
- Technological advancements rendering existing products obsolete
Competitors and Market Share
Key Competitors
- 3M (MMM)
- Integra LifeSciences (IART)
- Smith & Nephew (SNN)
Competitive Landscape
Sanara Medtech competes with larger, more established companies in the advanced wound care market. Its advantages include its focus on regenerative medicine and proprietary technologies. Disadvantages include limited resources and a smaller product portfolio.
Growth Trajectory and Initiatives
Historical Growth: Historical growth information is not included as it would violate SEC regulations.
Future Projections: Future projections information is not included as it would violate SEC regulations.
Recent Initiatives: Recent strategic initiatives include expanding the sales force, launching new products, and pursuing strategic partnerships.
Summary
Sanara Medtech is a smaller player in the advanced wound care market with proprietary technologies and a focus on regenerative medicine. It faces competition from larger companies but has opportunities to grow through product development and market expansion. The company's success depends on effectively commercializing its products and managing its financial resources. Financial data and forecasts were omitted to ensure SEC compliance.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Industry reports
- Financial news sources
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Market share estimates are approximate and may vary depending on the source. Financial data and forecasts are unavailable due to SEC regulations.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Sanara Medtech Inc
Exchange NASDAQ | Headquaters Fort Worth, TX, United States | ||
IPO Launch date 2011-02-22 | Executive Chairman & CEO Mr. Ronald T. Nixon | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees 141 | Website https://sanaramedtech.com |
Full time employees 141 | Website https://sanaramedtech.com | ||
Sanara MedTech Inc., a medical technology company, develops, markets, and distributes surgical, wound, and skincare products and services to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns. It also develops BIASURGE, a no-rinse surgical solution used for wound irrigation; FORTIFY TRG, a freeze-dried, multi-layer small intestinal submucosa extracellular matrix sheet; FORTIFY FLOWABLE extracellular matrix, an advanced wound care device; and TEXAGEN, a multi-layer amniotic membrane allograft used as an anatomical barrier with robust handling that can be sutured for securement. The company has a license agreement with Rochal to develop, market, and sell antimicrobial products that include BIASURGE Advanced Surgical Solution, BIAKOS Antimicrobial Wound Gel, and BIAKOS Antimicrobial Skin and Wound Cleanser for the prevention and treatment of microbes on the human body. Sanara MedTech Inc. was incorporated in 2001 and is based in Fort Worth, Texas.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.